Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

News

/News
510, 2015

European researchers: One out of five patients live longer using maintenance therapy

By |October 5th, 2015|News, Research|

This is important. There has been a lot of contradictory data on whether long term maintenance increases overall survival (OS) enough to justify the side effects and cost. This retrospective study, done on multiple myeloma patients in Europe, seems to support it.

110, 2015

Genetics and individualized myeloma therapy

By |October 1st, 2015|News, Research|

An important prognostic development was announced earlier this year by researchers in England. Check out this excerpt from MedPageToday’s special report, Mutations in Myeloma Predict Outcome:

2509, 2015

More about my decision to transplant and lingering side effects

By |September 25th, 2015|About Pat, News, Side effects, Tips, Transplants|

More and more companies are picking up the bill for dozens of new clinical trials. As the number of trials grow, I’m hopeful that some will ease up and broaden their criteria, allowing nonsectretors like me to participate.

2309, 2015

Update on ixazomib

By |September 23rd, 2015|News, Research|

Don’t sleep on ixazomib. My sources tell me to expect a flood of positive data about Takeda’s oral proteasome inhibitor (MLN9708) at this year’s ASH in Orlando. We should get a glimpse of things to come at the 15th International Myeloma Workshop (IMW 2015) in Rome, Italy, from September 23 to 26, 2015.

2009, 2015

MMRF CoMMpass Program ready to Rock ‘n Roll

By |September 20th, 2015|Inspirational, News, Research|

While our brand new CrowdCare Foundation continues to raise money to help support two specific T cell therapies, the MMRF embraces a much broader mission. I’m pleased to announce that the MMRF has now tested 1000 newly diagnosed patients that have agreed to be monitored from beginning to end. Tracking their progress–through a variety of […]

1909, 2015

New research partnership and more about Kyprolis

By |September 19th, 2015|News, Research, Side effects|

This is complicated stuff. Apparently Amgen, (now own Onyx who makes Kyprolis) is partnering up with others to try and move into the immunotherapy and T cell therapy space. I’m not sure I understand why they need a partner to do this, but money is BIG!
Amgen, Xencor to Partner on Cancer Immunotherapy, Inflammation Drugs
September 16 […]

1609, 2015

Alarming news from UK: No panobinostat, pomalidomide or Revlimid

By |September 16th, 2015|News, Supplements/Drugs|

Say it ain’t so! Don’t get diagnosed with multiple myeloma in England, Northern Ireland, Scotland or Wales. New austerity measures could result in an early death sentence for our brothers and sisters with myeloma in the UK. I wasn’t planning to write about this today, but I became so upset after reading an article on […]

1109, 2015

Dr. Tricot: “I’m pleased…”

By |September 11th, 2015|About Pat, Diagnostics, News, Side effects, Transplants|

As you’ve probably guessed by now, Dr. Tricot is a man of few words. Not known to use superlatives, a comment like, “I’m pleased with your results,” jumps out at you. But before everyone gets too excited, I need to add an asterisk. Turns out things are complicated.

909, 2015

Ixazomib granted priority review by FDA

By |September 9th, 2015|News|

The myeloma world doesn’t stop spinning just because I’m waiting for test results. With so much excitement surrounding the immunotherapies elotuzumab and daratumumab, another promising new drug, ixazomib (MLN9708), is often overlooked.

509, 2015

Promising results from another fledgling T cell therapy trial

By |September 5th, 2015|News, Research, Therapy, Transplants|

I’ve been openly excited about the prospects of various T cell therapies recently. Early T cell therapy may not be a cure, but it has the potential to be in time. Here’s a rundown of positive early results I found online Thursday, published in the Nature Medicine Journal and reviewed by Womens Fitness:
T-cell receptor therapy […]

409, 2015

Patient Snapshot Update: David from Tampa

By |September 4th, 2015|Caregivers, News, Side effects, Transplants|

Our dear friend, David from Tampa, had a busy summer. A family vacation, catching up work at his consulting business and all things medical are all great signs that he continues to recover successfully. I’ll get you links to the family stuff on CaringBridge at the end of the post. As you would expect, let’s […]

209, 2015

Two promising new myeloma therapies: ABT-199 and daratumumab

By |September 2nd, 2015|News, Research|

I just heard from a patient’s daughter. Her mother is joining a clinical trial for ABT-199 at Mayo Clinic in Minnesota. Apparently the myeloma team there is openly enthusiastic about the drug’s potential.

2708, 2015

BREAKING NEWS: Daratumumab pushes forward toward FDA approval

By |August 27th, 2015|News, Research, Side effects, Supplements/Drugs, Tips|

Important news as the promising new immunotherapy, daratumumab, continues to move swiftly toward FDA approval.

2608, 2015

Patients helping patients: Readers making a difference

By |August 26th, 2015|News, Research|

Efra, a reader from Israel, forwarded me an interesting article about cancer research–done at Mayo Clinic here in Jacksonvile. I got such a kick out of that. Love it or hate it, the internet helps keep us connected. What a small world!

2308, 2015

Dr. Ola Landgren to answer questions about treating high risk myeloma

By |August 23rd, 2015|News, Research, Therapy|

I’m part of an important broadcast Monday evening. Myeloma specialist, Dr. Ola Landgren, has been too busy to do interviews since moving his practice to Memorial Sloan-Kettering Cancer Center in New York. He’s making an exception of us. The topic: Can focusing on high risk myeloma help us find a cure? Remember, anyone who’s relapsed […]

2108, 2015

CrowdCare Foundation betting on T cell therapy

By |August 21st, 2015|Inspirational, News, Research|

After hearing from dozens of you about your peripheral neuropathy–and what you do to help minimize the symptoms–I’m working on a two part series about it, sharing tips from more than 20 patients; I’ll run the posts this weekend. In the meantime, here is CrowdCare Foundation’s official press release, announcing our support for two important, […]

1908, 2015

Peripheral neuropathy smacks me hard!

By |August 19th, 2015|About Pat, News, Side effects, Transplants|

A reader reminded me today, “Myeloma is not for wimps!” So true, Terri! Now at day 40, following my modified auto stem cell transplant, I continue to get stronger every day. But a new concern is threatening my recovery.

1408, 2015

Understanding our future: immunotherapies

By |August 14th, 2015|News, Research|

I just listened to one of the best and easiest to understand videos I’ve found, explaining how the new monoclonal antibodies (elotuzumab and daratumumab) work.

1208, 2015

BREAKING NEWS: MMRF helps push expanded access for dararumumab

By |August 12th, 2015|News, Research, Therapy|

Today is your last chance to participate in a focus group study using your smart phones. Amazon gift cards will be given to all who participate.

508, 2015

New myeloma staging system long overdue

By |August 5th, 2015|Diagnostics, News|

I think most myeloma experts would agree: its time for a myeloma staging system that incorporates genetic risk assessment. Italian specialist, Dr. Palumbo, and his team are proposing docs worldwide use their new system.